These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
391 related articles for article (PubMed ID: 34291399)
1. The place of vericiguat in the landscape of treatment for heart failure with reduced ejection fraction. Aimo A; Castiglione V; Vergaro G; Panichella G; Senni M; Lombardi CM; Emdin M Heart Fail Rev; 2022 Jul; 27(4):1165-1171. PubMed ID: 34291399 [TBL] [Abstract][Full Text] [Related]
2. Vericiguat for Heart Failure with Reduced Ejection Fraction. Lombardi CM; Cimino G; Pagnesi M; Dell'Aquila A; Tomasoni D; Ravera A; Inciardi R; Carubelli V; Vizzardi E; Nodari S; Emdin M; Aimo A Curr Cardiol Rep; 2021 Aug; 23(10):144. PubMed ID: 34410527 [TBL] [Abstract][Full Text] [Related]
3. Novel sGC Stimulators and sGC Activators for the Treatment of Heart Failure. Breitenstein S; Roessig L; Sandner P; Lewis KS Handb Exp Pharmacol; 2017; 243():225-247. PubMed ID: 27900610 [TBL] [Abstract][Full Text] [Related]
4. A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of the Efficacy and Safety of the Oral Soluble Guanylate Cyclase Stimulator: The VICTORIA Trial. Armstrong PW; Roessig L; Patel MJ; Anstrom KJ; Butler J; Voors AA; Lam CSP; Ponikowski P; Temple T; Pieske B; Ezekowitz J; Hernandez AF; Koglin J; O'Connor CM JACC Heart Fail; 2018 Feb; 6(2):96-104. PubMed ID: 29032136 [TBL] [Abstract][Full Text] [Related]
5. Drug Treatment of Heart Failure with Reduced Ejection Fraction: Defining the Role of Vericiguat. Coats AJS; Tolppanen H Drugs; 2021 Sep; 81(14):1599-1604. PubMed ID: 34478114 [TBL] [Abstract][Full Text] [Related]
6. Targeting Cyclic Guanosine Monophosphate to Treat Heart Failure: JACC Review Topic of the Week. Emdin M; Aimo A; Castiglione V; Vergaro G; Georgiopoulos G; Saccaro LF; Lombardi CM; Passino C; Cerbai E; Metra M; Senni M J Am Coll Cardiol; 2020 Oct; 76(15):1795-1807. PubMed ID: 33032741 [TBL] [Abstract][Full Text] [Related]
7. Vericiguat for the treatment of heart failure: mechanism of action and pharmacological properties compared with other emerging therapeutic options. Hulot JS; Trochu JN; Donal E; Galinier M; Logeart D; De Groote P; Juillière Y Expert Opin Pharmacother; 2021 Oct; 22(14):1847-1855. PubMed ID: 34074190 [TBL] [Abstract][Full Text] [Related]
8. Relative Efficacy of Sacubitril-Valsartan, Vericiguat, and SGLT2 Inhibitors in Heart Failure with Reduced Ejection Fraction: a Systematic Review and Network Meta-Analysis. Aimo A; Pateras K; Stamatelopoulos K; Bayes-Genis A; Lombardi CM; Passino C; Emdin M; Georgiopoulos G Cardiovasc Drugs Ther; 2021 Oct; 35(5):1067-1076. PubMed ID: 33074526 [TBL] [Abstract][Full Text] [Related]
9. A Systematic Review of the Effect of Vericiguat on Patients with Heart Failure. Sahana U; Wehland M; Simonsen U; Schulz H; Grimm D Int J Mol Sci; 2023 Jul; 24(14):. PubMed ID: 37511587 [TBL] [Abstract][Full Text] [Related]
10. Vericiguat: A Review in Chronic Heart Failure with Reduced Ejection Fraction. Kang C; Lamb YN Am J Cardiovasc Drugs; 2022 Jul; 22(4):451-459. PubMed ID: 35624347 [TBL] [Abstract][Full Text] [Related]
11. Development of vericiguat: The first soluble guanylate cyclase (sGC) stimulator launched for heart failure with reduced ejection fraction (HFrEF). Xia J; Hui N; Tian L; Liang C; Zhang J; Liu J; Wang J; Ren X; Xie X; Wang K Biomed Pharmacother; 2022 May; 149():112894. PubMed ID: 35367763 [TBL] [Abstract][Full Text] [Related]
12. [Soluble guanylate cyclase: restoration of the NO-sGC-cGMP signaling pathway activity. A new opportunity in the treatment of heart failure]. Belenkov YN; Kozhevnikova MV Kardiologiia; 2023 May; 63(5):68-76. PubMed ID: 37307211 [TBL] [Abstract][Full Text] [Related]